Prophase Labs Stock Analysis
| PRPH Stock | USD 0.38 0.01 2.56% |
ProPhase Labs is undervalued with Real Value of 3.73 and Target Price of 13.8. The main objective of ProPhase Labs stock analysis is to determine its intrinsic value, which is an estimate of what ProPhase Labs is worth, separate from its market price. There are two main types of ProPhase Labs' stock analysis: fundamental analysis and technical analysis.
The ProPhase Labs stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ProPhase Labs' ongoing operational relationships across important fundamental and technical indicators.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. ProPhase Stock Analysis Notes
The company has price-to-book ratio of 1.99. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. ProPhase Labs recorded a loss per share of 2.07. The entity last dividend was issued on the 24th of May 2022. The firm had 2:1 split on the 23rd of January 1997. ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Prophase Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 129 people. To find out more about ProPhase Labs contact Ted Karkus at 215 345 0919 or learn more at https://www.prophaselabs.com.ProPhase Labs Investment Alerts
| ProPhase Labs is way too risky over 90 days horizon | |
| ProPhase Labs has some characteristics of a very speculative penny stock | |
| ProPhase Labs appears to be risky and price may revert if volatility continues | |
| ProPhase Labs has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.77 M. Net Loss for the year was (49.52 M) with profit before overhead, payroll, taxes, and interest of 1.32 M. | |
| ProPhase Labs currently holds about 27.5 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProPhase Labs has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Is Apollomics Inc. Equity Warrant a candidate for recovery play - CPI Data Accurate Entry and Exit Point Alerts - newser.com |
ProPhase Labs Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ProPhase Labs previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ProPhase Largest EPS Surprises
Earnings surprises can significantly impact ProPhase Labs' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2004-10-28 | 2004-09-30 | 0.02 | 0.03 | 0.01 | 50 | ||
1997-08-13 | 1997-06-30 | 0.08 | 0.07 | -0.01 | 12 | ||
2010-11-10 | 2010-09-30 | 0.09 | 0.06 | -0.03 | 33 |
ProPhase Stock Institutional Investors
| Shares | Virtu Financial Llc | 2025-06-30 | 40.4 K | Two Sigma Securities, Llc | 2025-06-30 | 37.8 K | Bank Of New York Mellon Corp | 2025-06-30 | 37.1 K | United Capital Management Of Ks | 2025-06-30 | 34.7 K | Blackrock Inc | 2025-06-30 | 28 K | Bank Of America Corp | 2025-06-30 | 27.2 K | Northern Trust Corp | 2025-06-30 | 23.2 K | Bkb Wealth Advisors, Llc | 2025-06-30 | 19.6 K | Hpm Partners Llc | 2025-06-30 | 19 K | Vanguard Group Inc | 2025-06-30 | 408.3 K | Geode Capital Management, Llc | 2025-06-30 | 259.1 K |
ProPhase Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.68 M.ProPhase Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.11) | (1.05) | |
| Return On Capital Employed | (1.24) | (1.18) | |
| Return On Assets | (0.84) | (0.80) | |
| Return On Equity | (7.26) | (6.89) |
Management Efficiency
ProPhase Labs has return on total asset (ROA) of (0.2885) % which means that it has lost $0.2885 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7181) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -1.05. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -1.18. As of now, ProPhase Labs' Intangible Assets are increasing as compared to previous years. The ProPhase Labs' current Other Assets is estimated to increase to about 1.6 M, while Total Assets are projected to decrease to under 36.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.39 | 0.37 | |
| Tangible Book Value Per Share | (0.40) | (0.38) | |
| Enterprise Value Over EBITDA | (1.19) | (1.13) | |
| Price Book Value Ratio | 1.96 | 1.87 | |
| Enterprise Value Multiple | (1.19) | (1.13) | |
| Price Fair Value | 1.96 | 1.87 | |
| Enterprise Value | 44.1 M | 41.9 M |
Effective leadership at ProPhase Labs drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Technical Drivers
As of the 30th of October, ProPhase Labs holds the Semi Deviation of 6.88, risk adjusted performance of 0.0445, and Coefficient Of Variation of 1818.33. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProPhase Labs, as well as the relationship between them.ProPhase Labs Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Moving Average is predictive technique used to analyze ProPhase Labs price data points by creating a series of averages of different subsets of ProPhase Labs entire price series.
ProPhase Labs Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProPhase Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProPhase Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProPhase Labs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ProPhase Labs Outstanding Bonds
ProPhase Labs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ProPhase Labs uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ProPhase bonds can be classified according to their maturity, which is the date when ProPhase Labs has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US74348YAV39 Corp BondUS74348YAV39 | View | |
| US74348YDX67 Corp BondUS74348YDX67 | View | |
| PROSPECT CAP P Corp BondUS74348YEA55 | View | |
| US74348TAV44 Corp BondUS74348TAV44 | View | |
| PSEC 3437 15 OCT 28 Corp BondUS74348TAW27 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| PROLOGIS L P Corp BondUS74340XBH35 | View |
ProPhase Labs Predictive Daily Indicators
ProPhase Labs intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ProPhase Labs stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 252760.0 | |||
| Daily Balance Of Power | (0.17) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 0.39 | |||
| Day Typical Price | 0.39 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 48.92 |
ProPhase Labs Forecast Models
ProPhase Labs' time-series forecasting models are one of many ProPhase Labs' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProPhase Labs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ProPhase Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ProPhase Labs prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ProPhase shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ProPhase Labs. By using and applying ProPhase Stock analysis, traders can create a robust methodology for identifying ProPhase entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (6.25) | (5.94) | |
| Operating Profit Margin | (5.71) | (5.42) | |
| Net Loss | (7.88) | (7.49) | |
| Gross Profit Margin | (0.02) | (0.02) |
Current ProPhase Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ProPhase analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ProPhase analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 13.8 | Strong Buy | 1 | Odds |
Most ProPhase analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ProPhase stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ProPhase Labs, talking to its executives and customers, or listening to ProPhase conference calls.
ProPhase Stock Analysis Indicators
ProPhase Labs stock analysis indicators help investors evaluate how ProPhase Labs stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ProPhase Labs shares will generate the highest return on investment. By understating and applying ProPhase Labs stock analysis, traders can identify ProPhase Labs position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 1.6 M | |
| Long Term Debt | 11.7 M | |
| Common Stock Shares Outstanding | 19.1 M | |
| Total Stockholder Equity | 7.4 M | |
| Total Cashflows From Investing Activities | 2.4 M | |
| Tax Provision | 7.2 M | |
| Quarterly Earnings Growth Y O Y | -0.952 | |
| Property Plant And Equipment Net | 11.6 M | |
| Cash And Short Term Investments | 678 K | |
| Cash | 678 K | |
| Accounts Payable | 13.7 M | |
| Net Debt | 23.9 M | |
| 50 Day M A | 0.4362 | |
| Total Current Liabilities | 32.1 M | |
| Other Operating Expenses | 45.4 M | |
| Non Current Assets Total | 32.6 M | |
| Forward Price Earnings | 10.0908 | |
| Non Currrent Assets Other | 6 M | |
| Stock Based Compensation | 3.6 M |
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |